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IMPORTANCE The protection of telomeres 1 protein (POT1) is a critical component of the
shelterin complex, a multiple-protein machine that regulates telomere length and protects
telomere ends. Germline variants in POT1 have been linked to familial melanoma, and somatic
mutations are associated with a range of cancers including cutaneous T-cell lymphoma
(CTCL).
OBJECTIVE To characterize pathogenic variation in POT1 in families with melanoma to inform
clinical management.
DESIGN, SETTING, AND PARTICIPANTS In this case study and pedigree evaluation, analysis of
the pedigree of 1 patient with melanoma revealed a novel germline POT1 variant (p.I78T,
c.233T>C, chromosome 7, g.124870933A>G, GRCh38) that was subsequently found in 2 other
pedigrees obtained from the GenoMEL Consortium.
MAIN OUTCOMES AND MEASURES (1) Identification of the POT1 p.I78T variant; (2) evaluation
of the clinical features and characteristics of patients with this variant; (3) analysis of 3
pedigrees; (4) genomewide single-nucleotide polymorphism genotyping of germline DNA;
and (5) a somatic genetic analysis of available nevi and 1 melanoma lesion.
RESULTS The POT1 p.I78T variant was found in 3 melanoma pedigrees, all of persons who
self-reported as being of Jewish descent, and was shown to disrupt POT1-telomere binding.
A UV mutation signature was associated with nevus and melanoma formation in POT1 variant
carriers, and somatic mutations in driver genes such as BRAF, NRAS, and KIT were associated
with lesion development in these patients.
CONCLUSIONS AND RELEVANCE POT1 p.I78T is a newly identified, likely pathogenic, variant
meriting screening for in families with melanoma after more common predisposition genes
such as CDKN2A have been excluded. It could also be included as part of gene panel testing.
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A bout 10% of patients with melanoma have a family his-tory of the disease.1,2 The major melanoma predis-position genes are CDKN2A, CDK4, and BAP1.1 Ex-
tremely rare germline variants in the TERT promoter have also
been reported.3,4 More recently, components of the shelterin
complex, including in the Protection of Telomeres 1 (POT1)
gene, ACD, and TERF2IP,5-7 have been implicated. Patho-
genic POT1 variants promote telomere lengthening and dis-
rupt telomere stability.5,6 Importantly, these variants are rare
and potentially contribute to 1% to 5% of familial melanoma
cases.5,6 Pathogenic POT1 variants have also been associated
with predisposition to chronic lymphocytic leukemia (CLL),
cardiac angiosarcoma, glioma, and, more recently, colon
cancer.8
Methods
Institutional review board approval for this study was ob-
tained from the University of Leeds, University of Michigan,
Hospital Clínic de Barcelona, and Gustave Roussy. All pa-
tients included in this study signed informed consent. Exome
capture was performed using the SureSelect XT Human All-
Exon V5 platform (Agilent Technologies Inc), and sequencing
was performed using the Illumina HiSeq 2000 platform (Illu-
mina Inc). Telomere binding and length assays were per-
formed as previously described.5 For analysis methods, see
the Supplement.
Results
Our analysis began with the identification of a North Ameri-
can proband who had developed primary melanoma at age
Figure 1. Lesion Locations and 3 Pedigrees of Familial Melanoma, Including the Proband’s (Pedigree 1)
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In this proband and all 3 family pedigrees, the POT1 p.I78T variant was identified
as the likely pathogenic variant; all 3 pedigrees show the same base change.
A, Locations of lesions identified and excised from the proband, a POT1 variant
carrier (p.I78T, c.233T>C, chromosome 7, g.124870933A>G, GRCh38) at age 31
years. The primary melanoma on the neck was from the proband’s father, not
the proband, but is added here to illustrate its position. This melanoma
progressed to metastatic disease in the father. All numbered lesions were
sequenced. Samples numbered 550/551, 554/555, and 609/610 indicate 2
samples taken from the same lesion in these 3 cases. B, Pedigree structures for
all families identified to carry the p.I78T variant. Pedigree 1 corresponds to that
of the proband, and pedigrees 2 and 3 were identified from the GenoMEL
Consortium. Individuals represented by black shapes are variant carriers who
presented with melanoma. Individuals with no genotype were not tested. Ages,
reported in years, at the times of cancer diagnoses are shown in parentheses
when available.
Key Points
Question What is the association of the p.I78T variant in the
Protection of Telomeres 1 gene (POT1) with familial melanoma?
Findings We identified the POT1 p.I78T variant in 3 families of
Jewish heritage with melanoma in the family and provide evidence
that p.I78T interferes with POT1-telomere binding, a critical
disruption associated with tumor predisposition. These findings
suggest that the POT1 p.I78T variant may represent a founder
allele.
Meaning The identification of high-penetrance germline variants,
such as POT1 p.I78T, facilitates screening and counseling of at-risk
patients.
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31 years along with multiple dysplastic and compound and
dermal nevi (Figure 1A). He had also developed cutaneous
T-cell lymphoma (CTCL) and CLL and at ages 29 and 40
years, respectively. His father had developed CTCL,
CLL, melanoma in situ, and melanoma at ages 58, early 60s,
72, and 74 years, respectively (Figure 1B, pedigree 1).
The proband had sequenced his own genome on a next-
generation platform and had identified a POT1 variant
(p.I78T, c.233T>C, chromosome 7, g.124870933A>G,
GRCh38), the pathogenicity of which was unknown,
but it was predicted to be damaging by SIFT (score 0)9
and Polyphen-2 (score 1.0)10 analysis. To determine the
frequency of this variant in melanoma families, we ascer-
tained cases by consulting The Melanoma Genetics Consor-
tium (GenoMEL, http://www.genomel.org) and found
2 more carrier families; one of Spanish ancestry (1 case
among 171 families) (Figure 1B, pedigree 2; more detail on
the Spanish pedigree will be published elsewhere)
and the other of French descent6 (1 case among 157 families)
(Figure 1B, pedigree 3), both of whom had tested nega-
tive for other high-penetrance genes (eMethods in the
Supplement).
We next investigated whether the p.I78T variant had a
functional effect. An analysis of orthologous protein
sequences spanning 450 million years of evolutionary
distance showed complete conservation of the isoleucine
at position 78 (Figure 2A), and the protein model showed
that this residue is in close proximity to arginine 137,
another position found to be mutated in melanoma pedi-
grees (Figure 2B).6 This suggested that alteration of this
residue might impair POT1 single-stranded DNA binding.
To test this, we generated a POT1 complementary DNA
(cDNA) construct encoding the POT1 p.I78T protein and
found that it was severely impaired for its ability to bind
t o a p o l y n u c l e o t i d e t e l o m e r e - l i ke p r o b e ( I R 7 0 0 -
GGTTAGGGTTAGGGTTAGGG) (Figure 2C), as previously
seen with established melanoma-predisposing alleles.5 To
p rov i d e f u r t h e r f u n c t i o n a l p ro o f, we t r a n s d u c e d
Figure 2. Functional Analyses of the Pathogenicity of the POT1 p.I78T Variant
Protein locations in the POT1 OB domainBMultispecies POT1 protein sequence alignmentA





























































































































































































































































A, Multiple sequence alignment of the protection of telomeres 1 (POT1) protein
sequence in humans and 9 other species. Shown are amino acid positions 69 to
88, relative to human POT1, with the red arrow indicating the highly conserved
I78 residue. The best match in each protein alignment relative to human protein
is shown. B, The location of the I78 residue on the structure of the POT1
oligonucleotide/oligosaccharide-binding fold (OB) domain is indicated,
alongside another residue previously described as mutated in melanoma
families (R137). Green ribbons represent the OB domains; orange thread, the
telomere-like sequence. C, Telomere gel shift assays show that the POT1 p.I78T
protein is unable to bind to a telomere-like sequence. Wild-type (WT) POT1,
POT1 Y89C (a known pathogenic/disruptive variant) and POT1Δ (OB domain
deletion) constructs were used as controls.5 TNT1 and TNT2 indicate separate in
vitro translation reactions; pcDNA3 is an empty vector control. The arrow
indicates the presence of a POT1 protein-telomere complex formed by the
binding of in vitro translated POT1 protein to a telomere-like probe. Disruption
of this protein-DNA complex is associated with telomere instability and a loss of
telomere length control.
Research Brief Report Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma
606 JAMA Dermatology May 2019 Volume 155, Number 5 (Reprinted) jamadermatology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universidad de Barcelona User  on 04/27/2020
telomerase-positive HT1080 cells with either wild-type or
p.I78T POT1 cDNA constructs and cultured them through 45
population doublings. Telomeres in cells expressing the
p.I78T POT1 cDNA were elongated compared with cells
expressing wild-type POT1 (eMethods and eFigure 1 in the
Supplement).
After identifying 3 apparently unrelated families living
in different countries carrying the POT1 p.I78T variant, we
genotyped individuals using CoreExome single-nucleotide
polymorphism arrays (Illumina Inc) to estimate the coeffi-
cient of relatedness between carriers of the variant from dif-
ferent families and performed an analysis that suggested no
recent co-ancestry between the families. We were also able
to confirm the reported genetic relationships within each
family. Although the families were not closely related, the
sharing of genotypes around the POT1 gene in p.I78T vari-
ant carriers was consistent with a common haplotype across
some 4 megabase pairs (Mb) upstream and downstream of
the variant, suggesting that the p.I78T variant is a founder
event.
Interestingly, all 3 families self-reported being Jewish,
and we noted that the chromosome 7 g.124870933A>G
change has been reported in 3 individuals of Ashkenazi
Jewish descent in the Genome Aggregation Database
(gnomAD; chromosome 7 g.124510987A>G in GRCh37; allele
frequency in the Ashkenazi Jewish population, 0.0003105;
in all other populations, 0.000004305).11 Since patients
with germline POT1 variants are highly predisposed to mela-
noma development, we wondered if there would be any
defining features of the somatic landscape of melanocytic
lesions in these patients. Thus, we whole-exome sequenced
30 previously excised, formalin-fixed, paraffin-embedded
nevi from the proband in pedigree 1 (Figure 1) and a large
malignant melanoma from the proband’s father (anatomic
location illustrated in Figure 1A; eMethods in the Supple-
ment). Hotspot NRAS (Q61L, Q61K and Q61R) and BRAF
(V600E, V600D) mutations were identified in nevi, and
the melanoma was found to be KIT L576P positive
and to carry truncating NF1 and RASA2 mutations (eTable 1
in the Supplement), suggesting a prominent role for
the MAPK pathway. No TERT promoter mutations were
found.
Since a major driver of melanoma formation is exposure
to UV light, we next attempted to identify the imprint of
this mutagen on the melanoma genome. This analysis
revealed an average of 40.67 somatic ally acquired
m u t a t i o n s p e r M b o f e xo m e , o f w h i c h 8 7 % w e r e
C>T/G>A mutations. Extraction of mutation signatures from
the melanoma and nevi mutation catalogs identified
the UV-associated signature 7 (cosine similarity, 0.97).12
The number of mutations we identified in the father’s
melanoma (Figure 1B, pedigree 1) was higher than the
average observed following an analysis of 318 melanomas
(16.8 mutations/Mb) sequenced by The Cancer Genome
Atlas (TCGA),13 suggesting a contribution from UV light
to melanomagenesis in this POT1 mutation carrier. The
exome sequence of the CLL from the proband of pedigree
1 (Figure 1B) revealed few somatic mutations and no
enrichment for C>T mutations (Figure 3; eTable 2 in the
Supplement). All of the carriers in pedigrees 2 and 3
(Figure 1B) who had presented with melanoma had been
diagnosed with either superficial spreading or nodular
cutaneous melanoma. A histopathological analysis of the
melanoma from the p.I78T variant carrier (father, pedigree
1, Figure 1B) revealed that there were no defining features
distinguishable from sporadic melanoma (eFigure 2 in the
Supplement).
Discussion
The identification of pathogenic germline variants is of
critical importance because it informs genetic counselling
and allows individuals at high risk to be prioritized for
surveillance programs. In this study, we identified the
POT1 p.I78T variant in 3 unrelated melanoma pedigrees,
with evidence for the presence of this allele at a higher
frequency among Ashkenazi Jews. Interestingly, only 1
founder allele (p.V59G; CDKN2A) has previously been
associated with melanoma risk in people of Jewish
heritage.14
Notably, as illustrated in Figure 1B, in addition to mela-
noma, members of pedigree 1 have been diagnosed with
both CTCL and CLL, while pedigree 2 contains a variant car-
rier who developed melanoma and thyroid cancer. Collec-
tively, this clinical picture may suggest that this variant con-
tributes to a range of cancers. Indeed, somatic POT1 p.I78T
mutations have been found in a case of ovarian cancer
(COSMIC ID: COSM116403) and in a case of hepatosplenic
T-cell lymphoma.15































The top panel shows the exome-wide mutational spectra of the melanoma from
the father, and the bottom panel shows the exome-wide mutation spectra from
the proband’s chronic lymphocytic leukemia.
Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma Brief Report Research
jamadermatology.com (Reprinted) JAMA Dermatology May 2019 Volume 155, Number 5 607
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universidad de Barcelona User  on 04/27/2020
Limitations
Our study ascertained cases from GenoMEL, meaning that we
may not have a full picture of the spectrum of cancers ac-
quired by variant carriers. Additionally, while 4 of the 8 vari-
ant carriers illustrated in Figure 1B have developed mela-
noma, 4 variant carriers in pedigree 2 have not yet presented
with melanoma or any other malignancy, and these individu-
als were 19, 25, 50, and 55 years old, respectively, at last follow-
up. Thus, the penetrance of melanoma and other cancers in
p.I78T variant carriers is yet to be defined. Ultimately the iden-
tification of further pedigrees with the p.I78T variant will help
define its role in tumorigenesis.
Conclusions
The germline POT1 p.I78T variant is a candidate predisposi-
tion allele for melanoma development because it disrupts
POT1-telomere binding and promotes telomere lengthening.
Screening for this variant could be considered in individuals
found to be negative for pathogenic variants in established
melanoma predisposition genes such as CDKN2A, BAP1,
and CDK4, particularly in families of Jewish heritage
and/or with additional POT1-associated cancers such as
CTCL and CLL.16,17
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